Stem Cells is currently engaged in clinical development of its platform technology, HuCNS-SC^(R) cells (purified human neural stem cells), as a potential treatment for disorders of the central nervous system (CNS). As the first ever to conduct a U.S. clinical trial with human neural stem cells, StemCells is the only company, to date, with established human safety and preliminary efficacy data for these cells. The company’s comprehensive patent portfolio includes seminal technology in cell biology, with neural stem cell patents covering compositions of matter, methods of manufacture and methods of use. For more information, visit the company’s website at www.stemcellsinc.com.